Stay updated on Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial
Sign up to get notified when there's something new on the Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial page.

Latest updates to the Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check82 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check96 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check103 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
Stay in the know with updates to Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial page.